A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.

Radium 223 ◽

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

10.1158/1538-7445.sabcs16-ot1-04-05 ◽

2017 ◽

Author(s):

HS Rugo ◽

KC Drumea ◽

M Campone ◽

A Barnadas ◽

O Petrenciuc ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases

Annals of Oncology ◽

10.1093/annonc/mdw365.89 ◽

2016 ◽

Vol 27 ◽

pp. vi97 ◽

Cited By ~ 1

Author(s):

H. Rugo ◽

O. Petrenciuc ◽

A. Zhang ◽

R. Li ◽

R.E. Coleman

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients (pts) with bone metastases (mets).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps1104 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1104-TPS1104

Author(s):

Robert E. Coleman ◽

Liping Huang ◽

Oana Petrenciuc ◽

Paola Zaccarini

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223

Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs16-ot1-04-04 ◽

2017 ◽

Author(s):

RE Coleman ◽

G Fried ◽

O Petrenciuc ◽

A Sawhney ◽

R Li ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps622 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS622-TPS622

Author(s):

Robert E. Coleman ◽

Rui Li ◽

Amrita G. Sawhney ◽

Oana Petrenciuc ◽

Hope S. Rugo

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Hormone Receptor ◽

Controlled Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223

Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs15-ot2-01-05 ◽

2016 ◽

Author(s):

RE Coleman ◽

L Huang ◽

O Petrenciuc ◽

P Zaccarini ◽

HS Rugo

Keyword(s):

Controlled Trial ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Epidermal Growth ◽

Abstract OT2-01-11: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs15-ot2-01-11 ◽

2016 ◽

Author(s):

HS Rugo ◽

L Huang ◽

O Petrenciuc ◽

P Zaccarini ◽

RE Coleman

Keyword(s):

Controlled Trial ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Radium 223 ◽

Epidermal Growth ◽

Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

10.1158/0008-5472.sabcs13-ot3-2-10 ◽

2013 ◽

Cited By ~ 2

Author(s):

N Turner ◽

F André ◽

S Loibl ◽

J Ro ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Faculty of 1000 evaluation for Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717985574.793472568 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomised Controlled ◽

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70026-3 ◽

2013 ◽

Vol 14 (3) ◽

pp. 228-235 ◽

Cited By ~ 112

Author(s):

John FR Robertson ◽

Jean-Marc Ferrero ◽

Hugues Bourgeois ◽

Hagen Kennecke ◽

Richard H de Boer ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomised Controlled ◽